Ypsomed Holding Ag · SIX:YPSN
Ypsomed — H1 2015/16 Earnings Presentation
33 slides from Ypsomed's earnings presentation, Oct 28, 2015
Slide 1: Ypsomed – Presentation of 2015/16 Semiannual Results
Ypsomed – Presentation of 2015/16 Semiannual Results Zurich, October 28, 2015
Slide 2: Important notice
Important notice The information contained in this document has not been independently verified and no representation or warranty, expressed or implied, is made to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herei
Slide 3: Agenda
Agenda 1. Introduction 2. Operational business 3. Finances 4. Outlook 5. Questions and answers 3 | Ypsomed Holding AG | Presentation of Semiannual Results for 2015/16
Slide 4: Growth trajectory continues
Growth trajectory continues Increase in sales by CHF 9.3 million to CHF 157.8 million (+6.2%) In comparison with the period the previous year, EBIT increased by more than 50% to CHF 19.4 million (previous year CHF 12.9 million) Earnings per share increased from CHF 0.72 to CHF 1.20 Aboli
Slide 5: Growth despite ongoing challenging currency situation
Growth despite ongoing challenging currency situation 5 | Ypsomed Holding AG | Presentation of Semiannual Results for 2015/16
Slide 6: EBIT margin in double digits
EBIT margin in double digits 6 | Ypsomed Holding AG | Presentation of Semiannual Results for 2015/16
Slide 7: Agenda
Agenda 1. Introduction 2. Operational business 3. Finances 4. Outlook 5. Questions and answers 7 | Ypsomed Holding AG | Presentation of Semiannual Results for 2015/16
Slide 8: Injection systems
Injection systems 8 | Ypsomed Holding AG | Presentation of Semiannual Results for 2015/16
Slide 9: Sales trend Ypsomed Delivery Systems
Sales trend Ypsomed Delivery Systems 9 | Ypsomed Holding AG | Presentation of Semiannual Results for 2015/16
Slide 10: Customer base expanded
Customer base expanded Three new product launches in the reporting period 10 | Ypsomed Holding AG | Presentation of Semiannual Results for 2015/16
Slide 11: Delivery Systems growth driver: GLP-1 injection systems for AstraZeneca and GSK
Delivery Systems growth driver: GLP-1 injection systems for AstraZeneca and GSK 11 | Ypsomed Holding AG | Presentation of Semiannual Results for 2015/16
Slide 12: Smart Health – an investment in the future
Smart Health – an investment in the future 12 | Ypsomed Holding AG | Presentation of Semiannual Results for 2015/16
Slide 13: Diabetes care
Diabetes care 13 | Ypsomed Holding AG | Presentation of Semiannual Results for 2015/16
Slide 14: Sales trend mylife Diabetescare
Sales trend mylife™ Diabetescare 14 | Ypsomed Holding AG | Presentation of Semiannual Results for 2015/16
Slide 15: New safety products right on trend
New safety products right on trend Ypsomed benefits from new legislation 15 | Ypsomed Holding AG | Presentation of Semiannual Results for 2015/16
Slide 16: mylife OmniPod patient base increased by 19%
mylife™ OmniPod® patient base increased by 19% Patientenbasis 2011/12 2012/13 2013/14 2014/15 2015/16 Geschäftsjahr 16 | Ypsomed Holding AG | Presentation of Semiannual Results for 2015/16
Slide 17: mylife YpsoPump got CE Mark and is ready for market launch
mylife™ YpsoPump® got CE Mark and is ready for market launch in Germany, UK and Netherlands 17 | Ypsomed Holding AG | Presentation of Semiannual Results for 2015/16
Slide 18: mylife YpsoPump accessories are soon available
mylife™ YpsoPump® accessories are soon available: carrier bags, inserter, mylife™ software 18 | Ypsomed Holding AG | Presentation of Semiannual Results for 2015/16
Slide 19: Continuous job growth
Continuous job growth 19 | Ypsomed Holding AG | Presentation of Semiannual Results for 2015/16
Slide 20: Continuous job growth
Continuous job growth 20 | Ypsomed Holding AG | Presentation of Semiannual Results for 2015/16
Slide 21: Agenda
Agenda 1. Introduction 2. Operational business 3. Finances 4. Outlook 5. Questions and answers 21 | Ypsomed Holding AG | Presentation of Semiannual Results for 2015/16
Slide 22: Operating result increased by over 50%
Operating result increased by over 50% 22 | Ypsomed Holding AG | Presentation of Semiannual Results for 2015/16
Slide 23: Profitability continuously increased
Profitability continuously increased 23 | Ypsomed Holding AG | Presentation of Semiannual Results for 2015/16
Slide 24: EBITDA margin over 20%
EBITDA margin over 20% 24 | Ypsomed Holding AG | Presentation of Semiannual Results for 2015/16
Slide 25: Net profit margin is about 10%
Net profit margin is about 10% In the reporting period the participation in Bionime was impaired by CHF 0.7 million (previous year: impairment of CHF 1.2 million) 25 | Ypsomed Holding AG | Presentation of Semiannual Results for 2015/16
Slide 26: Ypsomed continues to invest in the future
Ypsomed continues to invest in the future 26 | Ypsomed Holding AG | Presentation of Semiannual Results for 2015/16
Slide 27: External financing reduced
External financing reduced 27 | Ypsomed Holding AG | Presentation of Semiannual Results for 2015/16
Slide 28: Positive free cash flow supports growth
Positive free cash flow supports growth 28 | Ypsomed Holding AG | Presentation of Semiannual Results for 2015/16
Slide 29: Agenda
Agenda 1. Introduction 2. Operational business 3. Finances 4. Outlook 5. Questions and answers 29 | Ypsomed Holding AG | Presentation of Semiannual Results for 2015/16
Slide 30: Outlook – 2015/16 financial year
Outlook – 2015/16 financial year Based on these positive developments, we will raise our forecast for the end of the financial year 2015/16 We expect a growth in turnover of around 10% and an EBIT of approximately CHF 41 million This is largely supported by increased sales, better utilisati
Slide 31: Important dates
Important dates Presentation of 2015/16 annual results May 20, 2016 Annual General Meeting June 29, 2016 31 | Ypsomed Holding AG | Presentation of Semiannual Results for 2015/16
Slide 32: Agenda
Agenda 1. Introduction 2. Operational business 3. Finances 4. Outlook 5. Questions and answers 32 | Ypsomed Holding AG | Presentation of Semiannual Results for 2015/16
Slide 33: Questions and Answers
Questions and Answers